Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04-26

AUTHORS

Simona Lapusan, Maria B. Vidriales, Xavier Thomas, Stephane de Botton, Anne Vekhoff, Ruoping Tang, Charles Dumontet, Rodica Morariu-Zamfir, John M. Lambert, Marie-Laure Ozoux, Philippe Poncelet, Jesus F. San Miguel, Ollivier Legrand, Daniel J. DeAngelo, Francis J. Giles, Jean-Pierre Marie

ABSTRACT

The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by ImmunoGen Inc. Phase I trials of AVE9633 were performed in patients with AML to evaluate tolerability, pharmacokinetics and pharmacodynamics. Three phase I studies of AVE9633 were performed in 54 patients with refractory/relapsed AML, evaluating drug infusion on day 1 of a 21-day cycle (Day 1 study), day 1 and 8 (Day 1/8 study) and day 1, 4 and 7 (Day 1/4/7 study) of a 28-day cycle. Toxicity was mainly allergic reaction during infusion (3 grade 3 bronchospasms). DLT was reached for the D1–D7 schedule at 150 mg/sqm (1 keratitis, 1 liver toxicity), and the MTD was set at 130 mg/sqm for this schedule. In the two other phases I, the DLT was not reached. In the Day 1/8 study, CD33 on peripheral blasts was saturated and down-modulated for doses of 75 mg/m2 × 2 or higher, which was correlated with WBC kinetics and plasma levels of AVE9633. Decrease of DM4/CD33 ratio on the blasts surface between day 1 and 8 was the rational for evaluating day 1/4/7 schedule. This induced relatively constant DM4/CD33 levels over the first 8 days, however no activity was noted. One CRp, one PR and biological activity in five other patients were observed in this study. The Day 1 and Day 1/4/7 studies were early discontinued because of drug inactivity at doses significantly higher than CD33 -saturating doses. No myelossuppression was observed at any trial of AVE9633. The pharmacokinetics/pharmacodynamics data obtained in these studies will provide very useful information for the design of the next generation of immunoconjugates. More... »

PAGES

1121-1131

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-011-9670-0

DOI

http://dx.doi.org/10.1007/s10637-011-9670-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043629304

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21519855


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Differentiation, Myelomonocytic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchial Spasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Hypersensitivity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoconjugates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maytansine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sialic Acid Binding Ig-like Lectin 3", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lapusan", 
        "givenName": "Simona", 
        "id": "sg:person.01025216261.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025216261.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Servicio de Haematologia, Hospital Universitario de Salamanca, Salamanca, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411258.b", 
          "name": [
            "Servicio de Haematologia, Hospital Universitario de Salamanca, Salamanca, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vidriales", 
        "givenName": "Maria B.", 
        "id": "sg:person.01163260720.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163260720.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukemia Unit Hematology Department, Edouard Herriot Hospital, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.412180.e", 
          "name": [
            "Leukemia Unit Hematology Department, Edouard Herriot Hospital, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "Xavier", 
        "id": "sg:person.01271000165.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271000165.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology Department, Institut Gustave Roussy, Villejuif, France", 
          "id": "http://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Hematology Department, Institut Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Botton", 
        "givenName": "Stephane", 
        "id": "sg:person.01123211416.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123211416.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vekhoff", 
        "givenName": "Anne", 
        "id": "sg:person.01362131264.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362131264.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tang", 
        "givenName": "Ruoping", 
        "id": "sg:person.010467152312.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010467152312.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leukemia Unit Hematology Department, Edouard Herriot Hospital, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.412180.e", 
          "name": [
            "Leukemia Unit Hematology Department, Edouard Herriot Hospital, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dumontet", 
        "givenName": "Charles", 
        "id": "sg:person.0577711132.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577711132.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology, Sanofi-aventis, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Oncology, Sanofi-aventis, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morariu-Zamfir", 
        "givenName": "Rodica", 
        "id": "sg:person.0751305553.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751305553.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ImmunoGen, Inc, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.420937.b", 
          "name": [
            "ImmunoGen, Inc, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambert", 
        "givenName": "John M.", 
        "id": "sg:person.0772040173.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772040173.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology, Sanofi-aventis, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Oncology, Sanofi-aventis, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozoux", 
        "givenName": "Marie-Laure", 
        "id": "sg:person.01266672531.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266672531.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biocytex, Marseille, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Biocytex, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poncelet", 
        "givenName": "Philippe", 
        "id": "sg:person.0723155247.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723155247.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Servicio de Haematologia, Hospital Universitario de Salamanca, Salamanca, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411258.b", 
          "name": [
            "Servicio de Haematologia, Hospital Universitario de Salamanca, Salamanca, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "San Miguel", 
        "givenName": "Jesus F.", 
        "id": "sg:person.0610231713.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610231713.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.462844.8", 
          "name": [
            "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France", 
            "Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legrand", 
        "givenName": "Ollivier", 
        "id": "sg:person.0752753564.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Dana-Farber Cancer Institue, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Department of Medical Oncology, Dana-Farber Cancer Institue, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "DeAngelo", 
        "givenName": "Daniel J.", 
        "id": "sg:person.01311422030.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311422030.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CTRC, San Antonio, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.267309.9", 
          "name": [
            "CTRC, San Antonio, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giles", 
        "givenName": "Francis J.", 
        "id": "sg:person.011165370517.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011165370517.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partement d\u2019H\u00e9matologie, H\u00f4pital Saint-Antoine, 184, rue du Faubourg Saint Antoine, 75571, Paris cedex 12, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France", 
            "Universit\u00e9 Pierre et Marie Curie-Paris 6, Paris, France", 
            "D\u00e9partement d\u2019H\u00e9matologie, H\u00f4pital Saint-Antoine, 184, rue du Faubourg Saint Antoine, 75571, Paris cedex 12, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marie", 
        "givenName": "Jean-Pierre", 
        "id": "sg:person.01064502270.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064502270.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2407-9-199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020277867", 
          "https://doi.org/10.1186/1471-2407-9-199"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-04-26", 
    "datePublishedReg": "2011-04-26", 
    "description": "The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by ImmunoGen Inc. Phase I trials of AVE9633 were performed in patients with AML to evaluate tolerability, pharmacokinetics and pharmacodynamics. Three phase I studies of AVE9633 were performed in 54 patients with refractory/relapsed AML, evaluating drug infusion on day 1 of a 21-day cycle (Day 1 study), day 1 and 8 (Day 1/8 study) and day 1, 4 and 7 (Day 1/4/7 study) of a 28-day cycle. Toxicity was mainly allergic reaction during infusion (3 grade 3 bronchospasms). DLT was reached for the D1\u2013D7 schedule at 150\u00a0mg/sqm (1 keratitis, 1 liver toxicity), and the MTD was set at 130\u00a0mg/sqm for this schedule. In the two other phases I, the DLT was not reached. In the Day 1/8 study, CD33 on peripheral blasts was saturated and down-modulated for doses of 75\u00a0mg/m2 \u00d7 2 or higher, which was correlated with WBC kinetics and plasma levels of AVE9633. Decrease of DM4/CD33 ratio on the blasts surface between day 1 and 8 was the rational for evaluating day 1/4/7 schedule. This induced relatively constant DM4/CD33 levels over the first 8\u00a0days, however no activity was noted. One CRp, one PR and biological activity in five other patients were observed in this study. The Day 1 and Day 1/4/7 studies were early discontinued because of drug inactivity at doses significantly higher than CD33 -saturating doses. No myelossuppression was observed at any trial of AVE9633. The pharmacokinetics/pharmacodynamics data obtained in these studies will provide very useful information for the design of the next generation of immunoconjugates.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-011-9670-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "keywords": [
      "day 1", 
      "refractory acute myeloid leukemia", 
      "phase I", 
      "phase I trial", 
      "phase I studies", 
      "antibody-maytansinoid conjugates", 
      "pharmacokinetics/pharmacodynamics data", 
      "acute myeloid leukemia", 
      "peripheral blasts", 
      "refractory/", 
      "adult patients", 
      "I trial", 
      "plasma levels", 
      "I studies", 
      "myeloid leukemia", 
      "drug infusion", 
      "allergic reactions", 
      "pharmacodynamic data", 
      "patients", 
      "doses", 
      "CD33", 
      "infusion", 
      "AML", 
      "trials", 
      "immunoconjugates", 
      "tolerability", 
      "pharmacodynamics", 
      "pharmacokinetics", 
      "CRP", 
      "leukemia", 
      "DLT", 
      "study", 
      "MTD", 
      "blast surface", 
      "schedule", 
      "conjugates", 
      "biological activity", 
      "efficacy", 
      "inactivity", 
      "levels", 
      "activity", 
      "toxicity", 
      "days", 
      "blasts", 
      "decrease", 
      "useful information", 
      "sqm", 
      "cycle", 
      "PR", 
      "data", 
      "ratio", 
      "information", 
      "next generation", 
      "reaction", 
      "generation", 
      "kinetics", 
      "design", 
      "surface"
    ], 
    "name": "Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia", 
    "pagination": "1121-1131", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043629304"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-011-9670-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21519855"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-011-9670-0", 
      "https://app.dimensions.ai/details/publication/pub.1043629304"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_539.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-011-9670-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9670-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9670-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9670-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9670-0'


 

This table displays all metadata directly associated to this object as RDF triples.

332 TRIPLES      22 PREDICATES      103 URIs      94 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-011-9670-0 schema:about N14193c93e3ba4697a37634008176155d
2 N2b0e4fc269754eb48dacda208eea7428
3 N2e93fb94fc1942c5a3e82324e8339fe5
4 N2f25223dc43c4cc29f3708db21223803
5 N71ded3c6358d45019e3b93419beac942
6 N761b32ddc89046a0ab9348dd53e186d1
7 N7986edcd243e440c89a0e59cd9d7c3b5
8 N952e381830884202b86f68158760b2d6
9 Na29afbba8707479293d30cd649fcc080
10 Nb8aa7016422a4179b713addbabec27d6
11 Nbb104ac76f794b2ca19eb2b79c04a6fc
12 Nd5bb64e67ba641e89761f1d9be7a7aaa
13 Ndf8a5bd3e9b243d6ac3a4f1ae453fdc0
14 Ne58574f5ac43437fa994a1af60097be9
15 Nf4f7cf5fb98747f4bbaad1b98fcb5c66
16 Nf5f4450dcf9e4e198d212062b4a76cf7
17 Nf708a96dd15e4d57b3614a6210994c21
18 Nfc6974e9d9c041ff9c07fa8f933669c3
19 anzsrc-for:11
20 anzsrc-for:1115
21 schema:author N46320d01d2c5404ba59b4b0d07c354f7
22 schema:citation sg:pub.10.1186/1471-2407-9-199
23 schema:datePublished 2011-04-26
24 schema:datePublishedReg 2011-04-26
25 schema:description The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by ImmunoGen Inc. Phase I trials of AVE9633 were performed in patients with AML to evaluate tolerability, pharmacokinetics and pharmacodynamics. Three phase I studies of AVE9633 were performed in 54 patients with refractory/relapsed AML, evaluating drug infusion on day 1 of a 21-day cycle (Day 1 study), day 1 and 8 (Day 1/8 study) and day 1, 4 and 7 (Day 1/4/7 study) of a 28-day cycle. Toxicity was mainly allergic reaction during infusion (3 grade 3 bronchospasms). DLT was reached for the D1–D7 schedule at 150 mg/sqm (1 keratitis, 1 liver toxicity), and the MTD was set at 130 mg/sqm for this schedule. In the two other phases I, the DLT was not reached. In the Day 1/8 study, CD33 on peripheral blasts was saturated and down-modulated for doses of 75 mg/m2 × 2 or higher, which was correlated with WBC kinetics and plasma levels of AVE9633. Decrease of DM4/CD33 ratio on the blasts surface between day 1 and 8 was the rational for evaluating day 1/4/7 schedule. This induced relatively constant DM4/CD33 levels over the first 8 days, however no activity was noted. One CRp, one PR and biological activity in five other patients were observed in this study. The Day 1 and Day 1/4/7 studies were early discontinued because of drug inactivity at doses significantly higher than CD33 -saturating doses. No myelossuppression was observed at any trial of AVE9633. The pharmacokinetics/pharmacodynamics data obtained in these studies will provide very useful information for the design of the next generation of immunoconjugates.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N10556f03d20f4e0986402abe8afce670
30 N8385794b159b4e86b762a80e2ef3d73e
31 sg:journal.1094201
32 schema:keywords AML
33 CD33
34 CRP
35 DLT
36 I studies
37 I trial
38 MTD
39 PR
40 activity
41 acute myeloid leukemia
42 adult patients
43 allergic reactions
44 antibody-maytansinoid conjugates
45 biological activity
46 blast surface
47 blasts
48 conjugates
49 cycle
50 data
51 day 1
52 days
53 decrease
54 design
55 doses
56 drug infusion
57 efficacy
58 generation
59 immunoconjugates
60 inactivity
61 information
62 infusion
63 kinetics
64 leukemia
65 levels
66 myeloid leukemia
67 next generation
68 patients
69 peripheral blasts
70 pharmacodynamic data
71 pharmacodynamics
72 pharmacokinetics
73 pharmacokinetics/pharmacodynamics data
74 phase I
75 phase I studies
76 phase I trial
77 plasma levels
78 ratio
79 reaction
80 refractory acute myeloid leukemia
81 refractory/
82 schedule
83 sqm
84 study
85 surface
86 tolerability
87 toxicity
88 trials
89 useful information
90 schema:name Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
91 schema:pagination 1121-1131
92 schema:productId Nc1d9a140aee444d29fdd2029c7019dc3
93 Nd630bea20a644f46a473eb0abfe30e49
94 Ndd1f3ab0823649f69a9d95986ae7d9a4
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043629304
96 https://doi.org/10.1007/s10637-011-9670-0
97 schema:sdDatePublished 2022-06-01T22:08
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N8db95ea1e9da41b98b4dadd563b4f026
100 schema:url https://doi.org/10.1007/s10637-011-9670-0
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N062f78df09694484af43e40a6f7a77aa rdf:first sg:person.01311422030.31
105 rdf:rest Na8254defad584fe5807ae96e9c093140
106 N10556f03d20f4e0986402abe8afce670 schema:issueNumber 3
107 rdf:type schema:PublicationIssue
108 N14193c93e3ba4697a37634008176155d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Male
110 rdf:type schema:DefinedTerm
111 N1635bd04c9a54ce9933800957a6a66cf rdf:first sg:person.0772040173.03
112 rdf:rest Nd6de77bdb5464ce3b407aa055276cecf
113 N195c18987b354da8bf3950c514aca031 rdf:first sg:person.01271000165.93
114 rdf:rest N3268832f917848f0bee97b7321373d2a
115 N29bcf0aa214c4d3392a15e99cfbb2ddb rdf:first sg:person.01163260720.23
116 rdf:rest N195c18987b354da8bf3950c514aca031
117 N2b0e4fc269754eb48dacda208eea7428 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Leukemia, Myeloid, Acute
119 rdf:type schema:DefinedTerm
120 N2ca08e1a25314253a2a0088d29033bf2 rdf:first sg:person.010467152312.87
121 rdf:rest Na93c0cb9c64e415b9db0749a097e63c9
122 N2e93fb94fc1942c5a3e82324e8339fe5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Sialic Acid Binding Ig-like Lectin 3
124 rdf:type schema:DefinedTerm
125 N2f25223dc43c4cc29f3708db21223803 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Antibodies, Monoclonal, Humanized
127 rdf:type schema:DefinedTerm
128 N3268832f917848f0bee97b7321373d2a rdf:first sg:person.01123211416.80
129 rdf:rest N7ff1dd286bed4a0a8390264ad729e3e0
130 N46320d01d2c5404ba59b4b0d07c354f7 rdf:first sg:person.01025216261.91
131 rdf:rest N29bcf0aa214c4d3392a15e99cfbb2ddb
132 N71ded3c6358d45019e3b93419beac942 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Adult
134 rdf:type schema:DefinedTerm
135 N761b32ddc89046a0ab9348dd53e186d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Aged
137 rdf:type schema:DefinedTerm
138 N7986edcd243e440c89a0e59cd9d7c3b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Bronchial Spasm
140 rdf:type schema:DefinedTerm
141 N7ff1dd286bed4a0a8390264ad729e3e0 rdf:first sg:person.01362131264.28
142 rdf:rest N2ca08e1a25314253a2a0088d29033bf2
143 N8385794b159b4e86b762a80e2ef3d73e schema:volumeNumber 30
144 rdf:type schema:PublicationVolume
145 N8c6077983b0749cbbb8e8394d8f6f06f rdf:first sg:person.0723155247.39
146 rdf:rest Nf4b3e8e74f7b467dbbc2fd3d7be53d1e
147 N8db95ea1e9da41b98b4dadd563b4f026 schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 N952e381830884202b86f68158760b2d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Antigens, Differentiation, Myelomonocytic
151 rdf:type schema:DefinedTerm
152 Na29afbba8707479293d30cd649fcc080 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Maytansine
154 rdf:type schema:DefinedTerm
155 Na372949984654ff7998fd4c9d2a4955f rdf:first sg:person.0752753564.08
156 rdf:rest N062f78df09694484af43e40a6f7a77aa
157 Na8254defad584fe5807ae96e9c093140 rdf:first sg:person.011165370517.24
158 rdf:rest Nc587aba593414450bf805ae31a5acd2f
159 Na93c0cb9c64e415b9db0749a097e63c9 rdf:first sg:person.0577711132.86
160 rdf:rest Nbf192454e83d4ba7ae81c41ef442da7d
161 Nb8aa7016422a4179b713addbabec27d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Aged, 80 and over
163 rdf:type schema:DefinedTerm
164 Nbb104ac76f794b2ca19eb2b79c04a6fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Drug Hypersensitivity
166 rdf:type schema:DefinedTerm
167 Nbf192454e83d4ba7ae81c41ef442da7d rdf:first sg:person.0751305553.02
168 rdf:rest N1635bd04c9a54ce9933800957a6a66cf
169 Nc1d9a140aee444d29fdd2029c7019dc3 schema:name dimensions_id
170 schema:value pub.1043629304
171 rdf:type schema:PropertyValue
172 Nc587aba593414450bf805ae31a5acd2f rdf:first sg:person.01064502270.46
173 rdf:rest rdf:nil
174 Nd5bb64e67ba641e89761f1d9be7a7aaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Female
176 rdf:type schema:DefinedTerm
177 Nd630bea20a644f46a473eb0abfe30e49 schema:name pubmed_id
178 schema:value 21519855
179 rdf:type schema:PropertyValue
180 Nd6de77bdb5464ce3b407aa055276cecf rdf:first sg:person.01266672531.34
181 rdf:rest N8c6077983b0749cbbb8e8394d8f6f06f
182 Ndd1f3ab0823649f69a9d95986ae7d9a4 schema:name doi
183 schema:value 10.1007/s10637-011-9670-0
184 rdf:type schema:PropertyValue
185 Ndf8a5bd3e9b243d6ac3a4f1ae453fdc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Humans
187 rdf:type schema:DefinedTerm
188 Ne58574f5ac43437fa994a1af60097be9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Infusions, Intravenous
190 rdf:type schema:DefinedTerm
191 Nf4b3e8e74f7b467dbbc2fd3d7be53d1e rdf:first sg:person.0610231713.03
192 rdf:rest Na372949984654ff7998fd4c9d2a4955f
193 Nf4f7cf5fb98747f4bbaad1b98fcb5c66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Antineoplastic Agents
195 rdf:type schema:DefinedTerm
196 Nf5f4450dcf9e4e198d212062b4a76cf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Antigens, CD
198 rdf:type schema:DefinedTerm
199 Nf708a96dd15e4d57b3614a6210994c21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Immunoconjugates
201 rdf:type schema:DefinedTerm
202 Nfc6974e9d9c041ff9c07fa8f933669c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Middle Aged
204 rdf:type schema:DefinedTerm
205 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
206 schema:name Medical and Health Sciences
207 rdf:type schema:DefinedTerm
208 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
209 schema:name Pharmacology and Pharmaceutical Sciences
210 rdf:type schema:DefinedTerm
211 sg:journal.1094201 schema:issn 0167-6997
212 1573-0646
213 schema:name Investigational New Drugs
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01025216261.91 schema:affiliation grid-institutes:grid.412370.3
217 schema:familyName Lapusan
218 schema:givenName Simona
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025216261.91
220 rdf:type schema:Person
221 sg:person.010467152312.87 schema:affiliation grid-institutes:grid.412370.3
222 schema:familyName Tang
223 schema:givenName Ruoping
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010467152312.87
225 rdf:type schema:Person
226 sg:person.01064502270.46 schema:affiliation grid-institutes:grid.412370.3
227 schema:familyName Marie
228 schema:givenName Jean-Pierre
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064502270.46
230 rdf:type schema:Person
231 sg:person.011165370517.24 schema:affiliation grid-institutes:grid.267309.9
232 schema:familyName Giles
233 schema:givenName Francis J.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011165370517.24
235 rdf:type schema:Person
236 sg:person.01123211416.80 schema:affiliation grid-institutes:grid.14925.3b
237 schema:familyName de Botton
238 schema:givenName Stephane
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123211416.80
240 rdf:type schema:Person
241 sg:person.01163260720.23 schema:affiliation grid-institutes:grid.411258.b
242 schema:familyName Vidriales
243 schema:givenName Maria B.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163260720.23
245 rdf:type schema:Person
246 sg:person.01266672531.34 schema:affiliation grid-institutes:grid.417924.d
247 schema:familyName Ozoux
248 schema:givenName Marie-Laure
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266672531.34
250 rdf:type schema:Person
251 sg:person.01271000165.93 schema:affiliation grid-institutes:grid.412180.e
252 schema:familyName Thomas
253 schema:givenName Xavier
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271000165.93
255 rdf:type schema:Person
256 sg:person.01311422030.31 schema:affiliation grid-institutes:grid.65499.37
257 schema:familyName DeAngelo
258 schema:givenName Daniel J.
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311422030.31
260 rdf:type schema:Person
261 sg:person.01362131264.28 schema:affiliation grid-institutes:grid.412370.3
262 schema:familyName Vekhoff
263 schema:givenName Anne
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362131264.28
265 rdf:type schema:Person
266 sg:person.0577711132.86 schema:affiliation grid-institutes:grid.412180.e
267 schema:familyName Dumontet
268 schema:givenName Charles
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577711132.86
270 rdf:type schema:Person
271 sg:person.0610231713.03 schema:affiliation grid-institutes:grid.411258.b
272 schema:familyName San Miguel
273 schema:givenName Jesus F.
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610231713.03
275 rdf:type schema:Person
276 sg:person.0723155247.39 schema:affiliation grid-institutes:None
277 schema:familyName Poncelet
278 schema:givenName Philippe
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723155247.39
280 rdf:type schema:Person
281 sg:person.0751305553.02 schema:affiliation grid-institutes:grid.417924.d
282 schema:familyName Morariu-Zamfir
283 schema:givenName Rodica
284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751305553.02
285 rdf:type schema:Person
286 sg:person.0752753564.08 schema:affiliation grid-institutes:grid.462844.8
287 schema:familyName Legrand
288 schema:givenName Ollivier
289 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08
290 rdf:type schema:Person
291 sg:person.0772040173.03 schema:affiliation grid-institutes:grid.420937.b
292 schema:familyName Lambert
293 schema:givenName John M.
294 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772040173.03
295 rdf:type schema:Person
296 sg:pub.10.1186/1471-2407-9-199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020277867
297 https://doi.org/10.1186/1471-2407-9-199
298 rdf:type schema:CreativeWork
299 grid-institutes:None schema:alternateName Biocytex, Marseille, France
300 schema:name Biocytex, Marseille, France
301 rdf:type schema:Organization
302 grid-institutes:grid.14925.3b schema:alternateName Hematology Department, Institut Gustave Roussy, Villejuif, France
303 schema:name Hematology Department, Institut Gustave Roussy, Villejuif, France
304 rdf:type schema:Organization
305 grid-institutes:grid.267309.9 schema:alternateName CTRC, San Antonio, TX, USA
306 schema:name CTRC, San Antonio, TX, USA
307 rdf:type schema:Organization
308 grid-institutes:grid.411258.b schema:alternateName Servicio de Haematologia, Hospital Universitario de Salamanca, Salamanca, Spain
309 schema:name Servicio de Haematologia, Hospital Universitario de Salamanca, Salamanca, Spain
310 rdf:type schema:Organization
311 grid-institutes:grid.412180.e schema:alternateName Leukemia Unit Hematology Department, Edouard Herriot Hospital, Lyon, France
312 schema:name Leukemia Unit Hematology Department, Edouard Herriot Hospital, Lyon, France
313 rdf:type schema:Organization
314 grid-institutes:grid.412370.3 schema:alternateName Département d’Hématologie, Hôpital Saint-Antoine, 184, rue du Faubourg Saint Antoine, 75571, Paris cedex 12, France
315 Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France
316 schema:name Département d’Hématologie, Hôpital Saint-Antoine, 184, rue du Faubourg Saint Antoine, 75571, Paris cedex 12, France
317 Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France
318 Université Pierre et Marie Curie-Paris 6, Paris, France
319 rdf:type schema:Organization
320 grid-institutes:grid.417924.d schema:alternateName Oncology, Sanofi-aventis, Paris, France
321 schema:name Oncology, Sanofi-aventis, Paris, France
322 rdf:type schema:Organization
323 grid-institutes:grid.420937.b schema:alternateName ImmunoGen, Inc, Cambridge, MA, USA
324 schema:name ImmunoGen, Inc, Cambridge, MA, USA
325 rdf:type schema:Organization
326 grid-institutes:grid.462844.8 schema:alternateName Université Pierre et Marie Curie-Paris 6, Paris, France
327 schema:name Hematology and Oncology Department, Saint-Antoine Hospital, AP-HP, Paris, France
328 Université Pierre et Marie Curie-Paris 6, Paris, France
329 rdf:type schema:Organization
330 grid-institutes:grid.65499.37 schema:alternateName Department of Medical Oncology, Dana-Farber Cancer Institue, Boston, MA, USA
331 schema:name Department of Medical Oncology, Dana-Farber Cancer Institue, Boston, MA, USA
332 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...